MARKET

ADYX

ADYX

Adynxx
EXMKT
0.0001
0.0000
0.00%
Opening 09:30 10/03 EDT
OPEN
--
PREV CLOSE
0.0001
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.375
52 WEEK LOW
0.0001
MARKET CAP
580.79
P/E (TTM)
-0.0000
1D
5D
1M
3M
1Y
5Y
SAGE Journals Publishes New Data Revealing NEXGEL’s SilverSeal Hydrogel Dressing Improves Postsurgical Scarring
Patients Treated with SilverSeal Experienced Significantly Less Scarring and Improved Skin Functionality Following Surgical Incision LANGHORNE, Pa., Oct. 03, 2022 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (NASDAQ: NXGL, NXGLW), (“NEXGEL” or the “Company”), a leadin...
GlobeNewswire · 4h ago
NEXGEL Appoints Dr. Leonard Nelson and Dr. Neil Chesen to Scientific Advisory Board
LANGHORNE, Pa., Sept. 29, 2022 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL, NXGLW), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced today that the C...
GlobeNewswire · 4d ago
NEXGEL to Report its Second Quarter 2022 Financial and Operating Results on August 10th
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for...
GlobeNewswire · 08/04 11:30
NEXGEL Launches MEDAGEL Hydroliner Pro Pads for Eyelash Protection During Cosmetic Extensions Service
The Company's Proprietary Hydrogel Technology Protects Lower Lashes and Allows for Gentle Removal LANGHORNE, Pa., July 26, 2022 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (NASDAQ: NXGL, NXGLW), (“NEXGEL” or the “Company”), a leading provider of ultra-gentle, high-wa...
GlobeNewswire · 07/26 11:30
Entera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for the Treatment of Osteoporosis; Miranda Toledano Assumes CEO Position
JERUSALEM, July 18, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered peptides and therapeutic proteins, announced today the execution of the following key milestones: The U.S. Food and Drug Administra...
GlobeNewswire · 07/18 11:05
NEXGEL and Partners for World Health Join Forces to Support Humanitarian Relief Efforts in Ukraine and Around the World
For Every Two Boxes of SilverSeal® Purchased, One is Donated to Those Suffering in Ukraine LANGHORNE, Pa., July 06, 2022 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (NASDAQ: NXGL, NXGLW), (“NEXGEL” or the “Company”), a leading provider of ultra-gentle, high-water-con...
GlobeNewswire · 07/06 11:30
NEXGEL to Present at the LD Micro Invitational XII on June 8, 2022
Langhorne, Pennsylvania--(Newsfile Corp. - June 1, 2022) - NEXGEL, Inc. (NASDAQ: NXGL) (NASDAQ: NXGLW) ("NEXGEL" or the "Company"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced...
Newsfile · 06/01 11:30
Entera Bio Board Member, Miranda Toledano, to Assume Role of Chief Business Officer, Chief Financial Officer, and Head of Corporate Strategy
BOSTON and JERUSALEM, May 16, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the appointment of Miranda Toledano, one of Entera’s existing board members,...
GlobeNewswire · 05/16 12:00
More
About ADYX
Adynxx Inc., formerly Alliqua BioMedical, Inc., is a clinical stage biopharmaceutical company. The Company is focused on development of non-opioid therapeutics for the treatment of pain and inflammatory diseases. Its AYX platform utilizes a proprietary technology of non-opioid, disease-modifying transcription factor decoys. Its pipeline includes brivoligide and AYX2. Brivoligide product candidate is a potent and selective inhibitor of the transcription factor EGR1. Brivoligide is being developed for the prevention of post-surgical pain. AYX2 is a potent inhibitor of Kruppel-like Factors (KLF) six, nine and 15, transcription factors that maintain neuronal and glial activities involved in pain. AYX2 is being developed for the long-term suppression of chronic pain.

Webull offers kinds of Adynxx Inc stock information, including EXMKT:ADYX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADYX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADYX stock methods without spending real money on the virtual paper trading platform.